Cambridge-based biopharmaceutical company, Akebia Therapeutics, Inc., has its sights set on developing and selling therapeutics for those suffering from kidney diseases. The firm's primary development focus is on Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase. The drug is currently in Phase III development, and the company is hoping it will be a game-changer in treating anemia due to chronic kidney disease (CKD) in both dialysis-dependent and non-dialysis dependent adult patients. Akebia Therapeutics also offers Auryxia, a ferric citrate that helps manage serum phosphorus levels in adult patients with DD-CKD on dialysis, as well as treat iron deficiency anemia in adult patients with CKD who are not undergoing dialysis. Akebia has entered into several strategic partnerships, including collaboration agreements with Mitsubishi Tanabe Pharma Corporation and Janssen Pharmaceutica NV, to advance the development and marketing of Vadadustat in Japan and Asia as well as hypoxia-inducible factor prolyl hydroxylase targeted compounds globally. Akebia Therapeutics was founded in 2007, making it relatively young compared to others in its industry, yet its future looks bright.
Akebia Therapeutics's ticker is AKBA
The company's shares trade on the NASDAQ stock exchange
They are based in Cambridge, Massachussets
There are 201-500 employees working at Akebia Therapeutics
It is akebia.com
Akebia Therapeutics is in the Healthcare sector
Akebia Therapeutics is in the Biotechnology industry
The following five companies are Akebia Therapeutics's industry peers: